The chemotherapy drugs used for colon cancer depend on the stage of the disease, but most regimens are built around a backbone of fluorouracil (5-FU) or its oral equivalent, capecitabine. These are typically combined with one or two additional drugs, most commonly oxaliplatin or irinotecan, to form the standard regimens known as FOLFOX, FOLFIRI, and CAPOX. Which combination your oncologist recommends depends on your cancer’s stage, its genetic profile, and how well you tolerate treatment.
The Main Chemotherapy Regimens
Three combination regimens account for the majority of colon cancer chemotherapy:
- FOLFOX: 5-FU, leucovorin, and oxaliplatin. This is the most widely used regimen for stage III colon cancer after surgery and is also common in stage IV disease.
- FOLFIRI: 5-FU, leucovorin, and irinotecan. Often used for metastatic colon cancer, especially as a second-line option or when oxaliplatin isn’t tolerable.
- CAPOX (also called CAPEOX or XELOX): Capecitabine and oxaliplatin. Capecitabine is a pill you take at home rather than receiving through an IV, which makes this regimen appealing for patients who want fewer clinic visits.
Leucovorin isn’t a chemotherapy drug itself. It’s a vitamin that enhances the cancer-killing effect of 5-FU, so you’ll see it listed alongside 5-FU in most regimens.
For metastatic disease that hasn’t responded to initial treatment, oncologists sometimes use a more aggressive four-drug combination called FOLFOXIRI, which adds both oxaliplatin and irinotecan to the 5-FU backbone. Some patients with stage III cancer who are older or have other health concerns may receive 5-FU with leucovorin alone, or capecitabine alone, skipping oxaliplatin entirely.
When Chemotherapy Is Recommended by Stage
Colon cancer at stage I rarely requires chemotherapy. Surgery alone is usually curative. Stage II is more nuanced: chemotherapy is generally reserved for cases considered high risk, such as tumors that have grown through the colon wall, have certain features under the microscope, or were removed with fewer lymph nodes than ideal. Most stage II patients do not need chemo.
Stage III is where chemotherapy becomes standard. After surgical removal of the tumor and nearby lymph nodes, adjuvant (post-surgery) chemotherapy with FOLFOX or CAPOX significantly reduces the chance of the cancer coming back. Without any post-operative chemotherapy, the three-year disease-free survival for stage III patients ranges from roughly 44% to 52%. Adding chemotherapy with a fluoropyrimidine drug improves overall survival by about 10 percentage points. When oxaliplatin is added on top of that (as in FOLFOX), disease-free survival improves by another 7 to 8 points, reaching about 66% at five years compared to roughly 59% with 5-FU alone.
Stage IV colon cancer, where the disease has spread to other organs, is treated with chemotherapy as a primary tool rather than just an add-on to surgery. FOLFOX, FOLFIRI, and CAPOX are all first-line options here, often combined with targeted therapies. If surgery can remove all visible disease, chemotherapy may be given before surgery to shrink tumors or afterward to reduce the risk of recurrence.
How Long Treatment Lasts
Chemotherapy is given in repeating cycles, each lasting two to three weeks. A cycle includes a treatment phase followed by a rest period so your body can recover before the next round.
For stage III patients, the traditional standard was six months of adjuvant chemotherapy. A large international study (the SCOT trial), along with a pooled analysis of six worldwide trials, found that three months of oxaliplatin-based chemotherapy was nearly as effective as six months for many patients, with significantly less toxicity. Three months of CAPOX has become the new standard for patients with lower-risk stage III disease (specifically, tumors that haven’t grown deeply into surrounding tissue and cancer in only a few lymph nodes). Patients with higher-risk stage III cancer may still benefit from the full six months.
For metastatic disease, treatment duration is more flexible. Chemotherapy may continue for several months, pause when the cancer is controlled, and restart if it progresses. This “stop and start” approach helps balance disease control with quality of life.
How Chemotherapy Is Delivered
FOLFOX and FOLFIRI are given intravenously. Most patients have a port surgically placed under the skin of the chest before treatment begins. This small device connects to a vein and makes repeated IV access easier and less painful than a standard needle stick each visit.
Both regimens involve a clinic visit for the initial infusion, followed by a continuous infusion of 5-FU delivered through a portable pump you take home. The pump is typically about the size of a baby bottle and connects to your port. You carry it in a pouch or fanny pack for about 46 to 48 hours before returning to have it disconnected.
CAPOX simplifies this process. Oxaliplatin is still given by IV at the clinic, but capecitabine replaces the 5-FU infusion. You take capecitabine tablets at home twice a day for 14 days, then take a 7-day break before the next cycle. This means fewer hours connected to a pump and fewer clinic visits overall.
Side Effects by Drug
Each drug in these regimens carries its own side effect profile, so what you experience depends on which combination you’re receiving.
Oxaliplatin’s signature side effect is nerve damage in the hands and feet, known as peripheral neuropathy. In the acute phase, it causes intense cold sensitivity: touching cold surfaces, drinking cold beverages, or even breathing cold air can trigger tingling, numbness, or pain in your fingers, toes, and throat. This reaction typically starts during or shortly after the infusion and fades within days. Over multiple cycles, however, a longer-lasting neuropathy can develop. In the SCOT trial, moderate-to-severe neuropathy affected 58% of patients who received six months of oxaliplatin-based chemo, compared to 25% of those who received three months. This nerve damage can persist for months or even years after treatment ends, which is a major reason the shorter treatment duration has gained favor. Dose adjustments are the most effective way to limit neuropathy severity during treatment.
5-FU and capecitabine share many side effects because capecitabine converts to 5-FU inside your body. Common effects include mouth sores, diarrhea, nausea, and low blood counts that increase infection risk. Capecitabine can also cause hand-foot syndrome, a condition where the palms and soles become red, swollen, tender, and may blister or peel. Keeping hands and feet moisturized, avoiding friction, and steering clear of hot water can help manage this.
Irinotecan (used in FOLFIRI) is particularly associated with diarrhea, which can be severe and require medication to control. It can also cause significant fatigue and hair thinning.
Targeted Therapies Paired With Chemo
For metastatic colon cancer, chemotherapy is frequently combined with targeted drugs that attack specific vulnerabilities in cancer cells. The choice depends on genetic testing of the tumor.
One common addition is a drug that blocks blood vessel growth to tumors, starving them of their blood supply. This type of drug can be paired with any of the standard chemotherapy regimens.
Another class of targeted therapy blocks a growth signal receptor on the surface of cancer cells. These drugs only work in tumors without certain mutations in the RAS genes (sometimes called “wild-type RAS”). If your tumor carries a RAS mutation, which roughly half of colon cancers do, these drugs won’t help. Tumor location also matters: these growth-signal blockers tend to work best in cancers that originate on the left side of the colon. Your oncologist will order molecular testing of your tumor before recommending any targeted therapy.
Immunotherapy for Specific Tumor Types
About 10 to 15% of colon cancers have a feature called microsatellite instability-high (MSI-H) or mismatch repair deficiency (dMMR), meaning the cancer cells have a broken DNA repair system. These tumors respond exceptionally well to immunotherapy drugs that help your immune system recognize and attack cancer cells.
The FDA has approved immunotherapy combinations as a first-line treatment for people with advanced MSI-H or dMMR colorectal cancer, which in some cases may replace chemotherapy entirely. Testing for this feature is now standard practice at diagnosis. If your tumor has this characteristic, your treatment plan may look very different from the traditional chemotherapy regimens, with potentially better outcomes and a different side effect profile.